Tirzepatide is an FDA-approved injectable medication used to help manage type 2 diabetes. It works by targeting GIP and GLP-1 receptors in the body, which help control blood sugar and body weight. Scientists created Tirzepatide by modifying a natural substance called GIP. Studies have shown that Tirzepatide can help people with type 2 diabetes lose weight more effectively than GLP-1 treatments alone. Additionally, a trial called SURMOUNT-1 is exploring its potential for weight loss in people without diabetes, to see if it is safe and effective for those who are overweight or have obesity.

Tirzepatide is administered as an injection under the skin. It is typically given once a week.

Studies have shown that Tirzepatide is effective in promoting weight loss, especially in individuals with type 2 diabetes. It has been found to be more effective than treatments targeting GLP-1 alone.

Current trials, such as SURMOUNT-1, are investigating its use for weight loss in people without diabetes. These studies aim to determine its safety and efficacy for a broader population.

Tirzepatide is primarily prescribed for people with type 2 diabetes. However, studies are evaluating its potential for weight loss in individuals without diabetes.